ABO2013 / Suzhou Abogen Biosci - LARVOL DELTA

Dose escalation study evaluating the safety, tolerability, and preliminary efficacy of ABOR2013 monotherapy or in combination with PD-1 monoclonal antibody in advanced non-small cell lung cancer with EGFR positive mutation (ChiCTR) - P1 | N=75 | Recruiting | Sponsor: The First Affiliated Hospital of Guangzhou Medical University; The First Affiliated Hospital of Guangzhou Medical University | Not yet recruiting ➔ Recruiting | Phase classification: PN/A ➔ P1

Enrollment open • Phase classification • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • EGFR

A novel EGFR neoantigen-specific mRNA cancer vaccine demonstrates immunogenicity and anti-tumor efficacy in human (AACR 2025) - P=N/A | "Notably, robust neoantigen-specific immune responses were detected with patients achieving complete remission or partial response, respectively. ABO2013, as a monotherapy and in combination with sintilimab, has exhibited a favorable safety profile and a robust neoantigen-specific immune response and promising antitumor activity, warranting further investigation in EGFR-mutated NSCLC population."

Clinical • IO biomarker • Tumor-specific neoantigens • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • EGFR